Yin, Guojiang
Li, Yue
Wei, Pengxiao
Ma, Xuyuan
Li, Bixi
Gan, Guosheng
Song, Xiaoyang
Article History
Received: 7 September 2023
Accepted: 17 February 2024
First Online: 22 February 2024
Declarations
:
: This prospective, randomized single-center trial was approved by the Institutional Review Board, General Hospital of Central Theater Command of People’s Liberation Army, Wuhan, China (reference number: [2022]020 − 01) and registered in the Chinese Clinical Trial Registry(ChiCTR2200061326, 21/06/2022). All methods were carried out in accordance with relevant guidelines and regulations. Written informed consent was obtained from all participants. All participants gave written informed consent.
: Not applicable.
: The authors declare no competing interests.